Cladribine‐based salvage regimen‐induced deep remission of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in leukemia phase

Han, Yong; Kong, Peiyan

doi:10.1002/hon.2683

Cited by 4 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A cladribine-based regimen was reported in 2020 for a patient with relapse after receiving three cycles of chemotherapy, mostly AML regimens [ 56 ]. The patient underwent inhibitor therapy targeting RUNX1 and intensive chemotherapies but no clinical benefits.…”

Section: Conventional Therapies and New Therapeutic Options For Bpdcnmentioning

confidence: 99%

Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?

Poussard

Angelot‐Delettre

Deconinck

2022

Cancers

View full text Add to dashboard Cite

No benchmark treatment exists for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Since the malignancy is chemo-sensitive, chemotherapy followed by hematopoietic stem cell transplantation remains an effective treatment. However, relapses frequently occur with the development of resistance. New options arising with the development of therapies targeting signaling pathways and epigenetic dysregulation have shown promising results. In this review, we focus on conventional therapies used to treat BPDCN and the novel therapeutic approaches that guide us toward the future management of BPDCN.

show abstract

Section: Conventional Therapies and New Therapeutic Options For Bpdcnmentioning

confidence: 99%

Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?

Poussard

Angelot‐Delettre

Deconinck

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…We have reported the application of CLAG+PLD in the successful treatment of a primary refractory blastic plasmacytoid dendritic cell tumors (BPDCN), 20 and synergism anti‐leukemia effects were observed in vitro. 21 Here, we aimed to compare the efficacy and toxicity of CLAG+PLD to explore whether there was any improvement with the addition of pegylated liposomal doxorubicin to CLAG.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy

Wilson

Konopleva

Khoury

et al. 2021

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Cladribine‐based salvage regimen‐induced deep remission of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in leukemia phase

Cited by 4 publications

References 8 publications

Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?

Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?

Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia

Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy

Contact Info

Product

Resources

About